MM&M Magazine Honors Dan Renick with Innovation Catalyst Award
We are very proud to announce that Medical Marketing & Media (MM&M) has named Precision Value & Health President Dan Renick as one of its Top 10 Innovation Catalysts for 2018. This prestigious award is presented each year by MM&M to the top 10 healthcare executives that have brought disruptive innovation to their clients. In naming Dan as one of 2018’s Innovation Catalysts, MM&M cited his work in the formation of our latest brands Precision Value & Health and Precision Xtract, as well as his many contributions to Precision’s numerous innovative products and services.
Dan will receive his award at MM&M’s annual Transforming Healthcare Conference to be held on Wednesday, May 16 in New York City. Congratulations Dan from all of us at Precision!
To read Dan’s profile, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.